Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 22
TB-500 in the Netherlands: legal status
TB-500 has no marketing authorisation in the Netherlands. This page explains how the Geneesmiddelenwet, the CBG-MEB register, and the WADA sport ban apply.
Tesamorelin Netherlands: import rules
Tesamorelin has no EU marketing authorisation. The Netherlands has no registered product. What Dutch law, CBG-MEB rules, and customs mean for personal import.
Tesamorelin Netherlands: regulatory status
Tesamorelin has no EU marketing authorisation. The EMA application was withdrawn in 2012. Here is what Dutch patients and clinicians need to know.
Tirzepatide in Netherlands: Mounjaro access
Mounjaro (tirzepatide) has held an EMA marketing authorisation in the Netherlands since 2022. Here is what the licence covers and how Dutch reimbursement works.
GLP-1 agonists and cardiac catheterization
A July 2026 study examines whether patients can safely continue semaglutide or tirzepatide before cardiac catheterization with moderate sedation.
GLP-1 drugs and mitochondria: a 2026 review
A 2026 meta-analysis found GLP-1 agonists improved bioenergetics and cut oxidative stress in human cell models, but rated the evidence certainty as very low.
Hengrui HRS-7535 oral GLP-1: Phase 3 data
Hengrui and Kailera reported Phase 3 results for HRS-7535, an oral GLP-1 drug, in July 2026. Here is what the peer-reviewed Phase 2 data shows.
Who shapes Mounjaro talk on X? Not doctors
A July 2026 study found non-medical accounts, not clinicians, drive Mounjaro (tirzepatide) talk on X. What the network data shows.
Semaglutide and bilateral NAION
A July 2026 case report describes bilateral NAION and branch retinal artery occlusion in a man on semaglutide, with partial visual recovery after stopping.
Semaglutide: dose predicts CV outcomes
A July 2026 study found semaglutide's heart benefits track dose more closely than weight loss.
GLP-1 drugs: fewer falls in older adults
Semaglutide and tirzepatide were associated with roughly half the femoral fracture rate versus DPP-4 inhibitors in older adults with type 2 diabetes.
What Semax costs in the Netherlands
Semax has no EMA or CBG-MEB authorisation, so there is no official Dutch pharmacy price and no GVS reimbursement. Here is what that means for Dutch readers.